Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

Sarepta Therapeutics is viewed favorably because interim ENDURE data showed no acute liver injury among 11 patients receiving prophylactic sirolimus, while non-prophylaxed patients had ALI rates of 17% in ambulatory and 33% in non-ambulatory cohorts, including a previously reported fatal case. The exploratory PRO analysis also supports Elevidys’ clinical value, with treated patients showing a slower decline in PROMIS mobility scores and a median time to first meaningful improvement of 1 year versus no response in controls. In addition, the $39M REGENX/UPenn patent settlement removes a legal overhang around the franchise, strengthening the company’s outlook for its core rare-disease platform.

Sarepta Therapeutics is viewed negatively because ELEVIDYS still lacks convincing randomized confirmation of meaningful functional benefit: neither Study 102 nor EMBARK showed statistically significant NSAA improvement, and the larger external-control gains remain unverified and methodologically weakened by post hoc analysis, missing data, and overlap with prior datasets. Commercially, that uncertainty is already showing up in softer execution, with 2Q26 ELEVIDYS revenue of $98.1M declining 3.8% quarter over quarter, while the company still faces payer skepticism and an unclear path to reversing the decline. The bear case is further reinforced by clinically meaningful safety risk, including a 19% treatment-related ALI rate across 715 commercially treated patients, 7% serious ALI, and prior fatal liver failure events, all of which could pressure adoption and threaten the PMO franchise if regulatory action follows.